{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T17:35:50Z","timestamp":1773509750901,"version":"3.50.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Leptomeningeal disease (LMD) in melanoma patients is associated with significant neurological sequela and has a dismal outcome, with survival measured typically in weeks. Despite the therapeutic benefit of targeted therapies and immunotherapies for Stage IV melanoma, patients with LMD do not typically benefit. A deeper understanding of the tumor microenvironment (TME) of LMD may provide more appropriate therapeutic selection. A retrospective analysis of subjects who underwent surgical resection with LMD (n=8) were profiled with seven color multiplex staining to evaluate the expression of the global immune suppressive hub - the signal transducer and activator of transcription 3 (STAT3) and for the presence of CD3+ T cells, CD68+ monocyte-derived cells, CD163+ immune suppressive macrophages, and CD11c+ cells [potential dendritic cells (DCs)] in association with the melanoma tumor marker S100B and DAPI for cellular nuclear identification. High-resolution cellular imaging and quantification was conducted using the Akoya Vectra Polaris. CD11c+ cells predominate in the TME (10% of total cells), along with immunosuppressive macrophages (2%). Another potential subset of DCs co-expressing CD11c+ and the CD163+ immunosuppressive marker is frequently present (8\/8 of specimens, 8%). Occasional CD3+ T cells are identified, especially in the stroma of the tumor (p=0.039). pSTAT3 nuclear expression is heterogeneous in the various immune cell populations. Occasional immune cluster interactions can be seen in the stroma and on the edge. In conclusion, the TME of LMD is largely devoid of CD3+ T cells but is enriched in immune suppression and innate immunity.<\/jats:p>","DOI":"10.3389\/fimmu.2021.745893","type":"journal-article","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T19:40:48Z","timestamp":1633894848000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["CD11c+CD163+ Cells and Signal Transducer and Activator of Transcription 3 (STAT3) Expression Are Common in Melanoma Leptomeningeal Disease"],"prefix":"10.3389","volume":"12","author":[{"given":"Hinda","family":"Najem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anantha","family":"Marisetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Horbinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason T.","family":"Huse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella C.","family":"Glitza Oliva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherise D.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya U.","family":"Kumthekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek A.","family":"Wainwright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiwen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej S.","family":"Lesniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jared K.","family":"Burks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy B.","family":"Heimberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12861","article-title":"Leptomeningeal Disease in Melanoma Patients: An Update to Treatment, Challenges, and Future Directions","volume":"33","author":"Glitza","year":"2020","journal-title":"Pigment Cell Melanoma Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s11060-019-03121-2","article-title":"Predictors of Survival in Metastatic Melanoma Patients With Leptomeningeal Disease (LMD)","volume":"142","author":"Ferguson","year":"2019","journal-title":"J Neurooncology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1200\/JCO.18.00204","article-title":"Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial","volume":"37","author":"Kluger","year":"2019","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.3390\/cancers12061640","article-title":"Melanoma Brain Metastases in the Era of Target Therapies: An Overview","volume":"12","author":"Becco","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in Patients With Val600Glu or Val600Lys BRAF-Mutant Melanoma Metastatic to the Brain (BREAK-MB): A Multicentre, Open-Label, Phase 2 Trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in Patients With Melanoma and Brain Metastases: An Open-Label, Phase 2 Trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for Patients With Melanoma or Non-Small-Cell Lung Cancer and Untreated Brain Metastases: Early Analysis of a Non-Randomised, Open-Label, Phase 2 Trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.3390\/cancers12092635","article-title":"Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients With Leptomeningeal Metastases","volume":"12","author":"T\u00e9tu","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30147","article-title":"Managing Leptomeningeal Melanoma Metastases in the Era of Immune and Targeted Therapy","volume":"139","author":"Smalley","year":"2016","journal-title":"Int J Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11060-020-03619-0","article-title":"Melanoma Brain Metastases Have Lower T-Cell Content and Microvessel Density Compared to Matched Extracranial Metastases","volume":"152","author":"Weiss","year":"2021","journal-title":"J Neurooncology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4161\/onci.22660","article-title":"Melanoma-Infiltrating Dendritic Cells: Limitations and Opportunities of Mouse Models","volume":"1","author":"Klarquist","year":"2012","journal-title":"Oncoimmunology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41419-020-2440-1","article-title":"Activation of STAT3 is a Key Event in TLR4 Signaling-Mediated Melanoma Progression","volume":"11","author":"Fu","year":"2020","journal-title":"Cell Death Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/17.4.1006","article-title":"IL-10 Inhibits Macrophage Activation and Proliferation by Distinct Signaling Mechanisms: Evidence for Stat3-Dependent and -Independent Pathways","volume":"17","author":"O'Farrell","year":"1998","journal-title":"EMBO J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.07.039","article-title":"STAT3 Activation in Macrophages Following Infection With Salmonella","volume":"321","author":"Lin","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nm1325","article-title":"Inhibiting Stat3 Signaling in the Hematopoietic System Elicits Multicomponent Antitumor Immunity","volume":"11","author":"Kortylewski","year":"2005","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-004747","article-title":"IL-2 Regulates FOXP3 Expression in Human CD4+CD25+ Regulatory T Cells Through a STAT-Dependent Mechanism and Induces the Expansion of These Cells In Vivo","volume":"108","author":"Zorn","year":"2006","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-1429","article-title":"Molecular Basis for the Critical Role of Suppressor of Cytokine Signaling-1 in Melanoma Brain Metastasis","volume":"68","author":"Huang","year":"2008","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3337","article-title":"CSF-1R Inhibition Alters Macrophage Polarization and Blocks Glioma Progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"14281","DOI":"10.1038\/s41598-019-50656-5","article-title":"Stimulator of Interferon Genes (STING) Activation Exacerbates Experimental Colitis in Mice","volume":"9","author":"Martin","year":"2019","journal-title":"Sci Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-4110","article-title":"Anti\u2013PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells","volume":"26","author":"Rao","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/s12885-015-1377-8","article-title":"Inhibition of Colony Stimulating Factor-1 Receptor Improves Antitumor Efficacy of BRAF Inhibition","volume":"15","author":"Mok","year":"2015","journal-title":"BMC Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.621039","article-title":"A Novel Inflammatory Dendritic Cell That Is Abundant and Contiguous to T Cells in the Kidneys of Patients With Lupus Nephritis","volume":"12","author":"Parikh","year":"2021","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600895","article-title":"Accumulation of CD11c+CD163+ Adipose Tissue Macrophages Through Upregulation of Intracellular 11\u03b2-HSD1 in Human Obesity","volume":"197","author":"Nakajima","year":"2016","journal-title":"J Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e001053","DOI":"10.1136\/jitc-2020-001053","article-title":"CD163+ Cytokine-Producing cDC2 Stimulate Intratumoral Type 1 T Cell Responses in HPV16-Induced Oropharyngeal Cancer","volume":"8","author":"Santegoets","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2020.02.010","article-title":"The Ontogenetic Path of Human Dendritic Cells","volume":"120","author":"Amon","year":"2020","journal-title":"Mol Immunol"},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-21-1694","article-title":"Single Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases","author":"Smalley","year":"2021"},{"key":"B28","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3390\/cancers11040537","article-title":"A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials","volume":"11","author":"Srivastava","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0085-8","article-title":"A Natural Killer-Dendritic Cell Axis Defines Checkpoint Therapy-Responsive Tumor Microenvironments","volume":"24","author":"Barry","year":"2018","journal-title":"Nat Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01148","article-title":"Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells","volume":"9","author":"Tucci","year":"2019","journal-title":"Front Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.745893\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T16:46:10Z","timestamp":1673455570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.745893\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,8]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2021.745893"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.745893","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,8]]},"article-number":"745893"}}